Drugs / ChAdOx1-S
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT05087368 | Dec 2021 → Apr 2022 | COVID-19 | D'Or Institute for Research and Education | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05812586 | Mar → Jun 2023 | COVID-19 | D'Or Institute for Research and Education | Unknown | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05293665 Comparator | Mar → Nov 2022 | — | Vaxxinity, Inc. | Unknown | No outcome recorded |
| Phase 3 | NCT05007951 Comparator | Aug 2021 → Oct 2023 | COVID-19 | SK Bioscience Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ChAdOx1-S | “randomized 2:1:1 to receive either recombinant protein (SCB-2019, Clover), adenovirus-vector (ChAdOx1-S, AstraZeneca/Fiocruz), or mRNA (BNT162b2, Pfizer/Wyeth).” PMID 38762360 ↗ May 2024 |
| Known as | Vaxzevria | “ChAdOx1-S (Vaxzevria, AstraZeneca)” PMID 37711219 ↗ Sep 2023 |
| Modality | Vaccine | “GBP510 (Test vaccine) and ChAdOx1-S (Control vaccine)” NCT05007951 ↗ |
| Route | Intramuscular | “ChAdOx1-S vaccine, 0.5 mL suspension with approximately 5.0 × 10˄10 viral particles, intramuscular injection” NCT05293665 ↗ |